ALKS|Alkermes Plc|가격:29.920|Chg%:0.55

자세한 내용은 Alkermes Plc 회사

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc 정보



종목 코드 ALKS

회사 이름Alkermes Plc

상장일Jul 16, 1991

CEOPops (Richard F)

직원 수1800

유형Ordinary Share

회계 연도 종료Jul 16

주소Connaught House

도시DUBLIN

증권 거래소NASDAQ OMX - NASDAQ BASIC

국가Ireland

우편 번호D04 C5Y6

전화35317728000

웹사이트https://www.alkermes.com/

종목 코드 ALKS

상장일Jul 16, 1991

CEOPops (Richard F)

Alkermes Plc의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.38M

+6.34%

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

235.63K

-1.73%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

89.39K

-4.47%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+19.59%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+20.92%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+10.90%

Ms. Nancy S. Lurker

Independent Director

10.71K

+56.88%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Mr. C. Todd Nichols

Senior Vice President, Chief Commercial Officer

--

이름

이름/직위

직위

주식 보유

변동

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.38M

+6.34%

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

235.63K

-1.73%

Mr. Shane M. Cooke

Independent Director

103.74K

--

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

89.39K

-4.47%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+19.59%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+20.92%

수익 분석

통화: USD마지막 업데이트: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

VIVITROL

121.13M

30.73%

LYBALVI

98.25M

24.92%

ARISTADA

98.05M

24.87%

Royalty Revenue - VUMERITY

32.12M

8.15%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.18M

7.66%

기타

14.46M

3.67%

기업이 아직 관련 데이터를 공개하지 않았습니다.

사업별

지역별

사업별USD

이름

수익

비율

VIVITROL

121.13M

30.73%

LYBALVI

98.25M

24.92%

ARISTADA

98.05M

24.87%

Royalty Revenue - VUMERITY

32.12M

8.15%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.18M

7.66%

기타

14.46M

3.67%

주식 보유 통계

마지막 업데이트: Sat, Feb 21

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

14.44%

The Vanguard Group, Inc.

10.77%

Baker Bros. Advisors LP

6.01%

State Street Investment Management (US)

5.68%

T. Rowe Price Associates, Inc.

5.28%

기타

57.81%

주주

비율

BlackRock Institutional Trust Company, N.A.

14.44%

The Vanguard Group, Inc.

10.77%

Baker Bros. Advisors LP

6.01%

State Street Investment Management (US)

5.68%

T. Rowe Price Associates, Inc.

5.28%

기타

57.81%

주주 유형

주주

비율

Investment Advisor

54.83%

Investment Advisor/Hedge Fund

29.39%

Hedge Fund

19.23%

Research Firm

2.39%

Pension Fund

2.16%

Individual Investor

1.59%

Sovereign Wealth Fund

1.17%

Bank and Trust

0.48%

Private Equity

0.42%

기관 주식 보유



마지막 업데이트: Mon, Dec 8

보고 기간

기관 수

보유 주식

비율

변동

2025Q4

744

175.23M

117.54%

-23.12K

2025Q3

767

175.30M

122.16%

+2.11M

2025Q2

769

173.38M

125.62%

-4.15M

2025Q1

759

177.46M

124.05%

-27.05M

2024Q4

734

172.08M

130.58%

-12.03M

2024Q3

705

184.36M

134.23%

-884.11K

2024Q2

687

185.17M

126.42%

+3.87M

2024Q1

659

181.61M

124.10%

-28.36M

2023Q4

633

182.01M

111.83%

+12.84M

2023Q3

601

169.31M

104.05%

+9.33M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

23.65M

14.33%

-72.87K

-0.31%

Sep 30, 2025

The Vanguard Group, Inc.

18.13M

10.98%

-325.52K

-1.76%

Sep 30, 2025

Baker Bros. Advisors LP

8.09M

4.9%

+1.68M

+26.22%

Sep 30, 2025

State Street Investment Management (US)

8.54M

5.17%

+332.10K

+4.05%

Sep 30, 2025

T. Rowe Price Associates, Inc.

10.05M

6.09%

+189.56K

+1.92%

Sep 30, 2025

Renaissance Technologies LLC

6.29M

3.81%

+482.37K

+8.30%

Sep 30, 2025

American Century Investment Management, Inc.

4.40M

2.66%

+740.25K

+20.24%

Sep 30, 2025

JP Morgan Asset Management

3.62M

2.19%

-326.93K

-8.29%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

3.70M

2.24%

+601.36K

+19.42%

Sep 30, 2025

Geode Capital Management, L.L.C.

4.06M

2.46%

+37.84K

+0.94%

Sep 30, 2025

주식 배당금



지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

데이터 없음

주식 분할



날짜

배당락일

유형

비율

데이터 없음

날짜

배당락일

유형

비율

데이터 없음

Alkermes Plc

자세한 내용은 Alkermes Plc 회사

Alkermes Plc 정보

Alkermes Plc의 회사 임원진

수익 분석

주식 보유 통계

기관 주식 보유

주주 활동

관련 ETF

주식 배당금

주식 분할